N Engl J Med 2012 ; 367 : 1198-1207. Huib A.M. Kerstjens, M.D., Michael Engel, M.D., Ronald Dahl, M.D., Pierluigi Paggiaro, M.D., Ekkehard Beck, M.D.,

Slides:

Advertisements

Similar presentations

New Therapeutic Options for COPD

Advertisements

UPLIFT Understanding Potential Long-term Impacts on Function with Tiotropium Adapted from Tashkin et al. NEJM 2008: 359: Please be advised that.

Planning, COPD Hot Topics and CSA preparation Ruth Gooch 11/1/12.

USE OF STEROIDS IN PATIENTS WITH COPD EXACERBATION Richard C. Walls.

Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.

Criner et al. NEJM 2014: 370; 23 Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE) Presented by Ali Naqvi, MD.

COPD MANAGEMENT FALLS SHORT AT RCRMC Jean Solomon, M.D.

Inhaled corticosteroids in preschool asthmatic children

HIGH DOSES OF VITAMIN D TO REDUCE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMIZED TRIAL An Lehouck, PhD; Chantal Mathieu, MD, PhD;

Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.

Diagnosing asthma History & Physical examination Measurements of lung function – Spirometry – Peak expiratory flow Measurements of airway hyperresponsiveness.

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

Pulmonary-Allergy Drugs Advisory Committee January 17, FLOVENT ® DISKUS ® NDA , S004 GlaxoSmithKline Pulmonary-Allergy Drugs Advisory Committee.

Asma na Infância Renato T. Stein, M.D. Pontifícia Universidade Católica Porto Alegre, Brazil.

AHEAD COSMOS and COMPASS Studies. The AHEAD Study.

Definition COPD def- A disease state characterized by air flow limitation that is not fully reversible It is expected to be the 3 rd leading cause of.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

INPULSIS® trial design and baseline characteristics

Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in the Treatment of Adults with Chronic Asthma Kevin Dennis Pacific University School.

Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma Stephen P. Peters, M.D., Ph.D., Susan J. Kunselman, M.A., Nikolina Icitovic, M.A.S.,

Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

내과 R2 이지훈 N Engl J Med Sep 8.

Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.

Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):

Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.

Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.

RESPONSE TO ADD-ON INHALED CORTICOSTEROIDS IN COPD BASED ON AIRWAY HYPERRESPONSIVENESS TO MANNITOL Andreas Scherr, MD ; Salome Schafroth Török, MD ; Anja.

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation Michael Camilleri, M.D., Rene Kerstens, M.Sc., An Rykx, Ph.D., and Lieve Vandeplassche,

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;

Lancet Oncol 2012; 13: 528–38 Vincent A Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu-Chou Su, Mengzhao.

Safety of long-acting β-agonists for the treatment of asthma : clearing the air 장 나 은 Gustavo J Rodrigo, Jose A Castro-Rodrıguez Thorax 2012;

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Everolimus for Advanced Pancreatic Neuroendocrine Tumors N Engl J Med 2011;364: R4. 박선희 / Prof. 동석호.

Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma* A Randomized, Double-Blind Trial Klaus F. Rabe, MD, PhD;

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,

Journal of the American College of Cardiology Vol. 61, No. 4, 2013 Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation.

An effective COPD case finding strategy in Primary Care

The Advanced Role of Tiotropium in

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE):

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

Research where it is most needed National Respiratory Strategy

Once-daily tiotropium add-on to at least ICS improves control and reduces exacerbation risk in symptomatic asthma, independent of serum IgE or blood.

HOPE: Heart Outcomes Prevention Evaluation study

Practical Recommendations for COPD:

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma Stanley J. Szefler, MD, Kevin Murphy,

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

COPD Exacerbation (1) C.L.I.P.S.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Michael E. Wechsler, MD Mayo Clinic Proceedings

Michael Mellon, MD Journal of Allergy and Clinical Immunology

Revisione dei Trial Clinici sulle Malattie Ostruttive dell’ultimo anno

Roflumilast negli studi di Fase III: i dati di efficacia

The efficacy and safety of omalizumab in pediatric allergic asthma

Chronic Obstructive Pulmonary Disease

Roflumilast: il programma di sviluppo clinico

Identificazione del sottogruppo di pazienti responsivi

The Journal of Allergy and Clinical Immunology: In Practice

Eckard Hamelmann, MD, Eric D

Roflumilast in aggiunta ai corticosteroidi inalatori

Practical Recommendations for COPD:

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Where Does Anticholinergic Therapy Fit in Moderate to Severe Asthma?

Presenter Disclosure Information

Presentation transcript:

N Engl J Med 2012 ; 367 : Huib A.M. Kerstjens, M.D., Michael Engel, M.D., Ronald Dahl, M.D., Pierluigi Paggiaro, M.D., Ekkehard Beck, M.D., Mark Vandewalker, M.D., Ralf Sigmund, Dipl.Math., Wolfgang Seibold, M.D., Petra Moroni-Zentgraf, M.D., and Eric D. Bateman, M.D. Journal conference R2 Seon-Hye Kim, Prof. Hong-Mo Kang

BACKGROUND : Poorly controlled asthma  Recurring symptoms and exacerbations despite the use of preferred controller drugs (i.e., inhaled glucocorticoids ± inhaled long-acting beta-agonists [LABAs]).  Adding a long-acting anticholinergic bronchodilator (tiotropium)  Not been evaluated in long-term clinical trials

EVALUATION (PrimoTinAasthma 1 & 2 trials) : the efficacy & safety of adding tiotropium as compared with placebo, to a treatment regimen of glucocorticoids and LABAs. Long-acting anticholinergic bronchodilator: Tiotropium : the most widely used long-acting bronchodilator worldwide for the treatment of COPD.

Inclusion criteria  Age : 18 yrs and 75 yrs  ≥ 5yrs Hx. of asthma & diagnosed before the age of 40yrs.  Post-bronchodilator FEV1 <80% or FVC<70% + ICS & LABAs  ≥ 1 exacerbation in the previous year + systemic glucocorticoids  Non-smokers or < 10PY smoking Hx Exclusion criteria  Past diagnosis of COPD  Serious co-existing illnesses  Concurrent use of anticholinergic bronchodilators

PrimoTinAasthma 1 & 2 trials 2 replicate trials : Randomized, double-blind, placebo-controlled, parallel-group design. Duration : 48-week study period Multicenter trial : Australia, Canada, Denmark, Great Britain, Germany, Italy, Japan, Taiwan, The Netherlands, New Zealand, Serbia, South Africa, Turkey. 5 μg of tiotropium or matching placebo each morning add-on therapy to individual pre-trial maintenance asthma therapy consisting of high-dose ICS & LABAs.

Primary end points 1) peak FEV1 response 2) trough FEV1 response 3) time to the 1st severe asthma exacerbation (need systemic glucocorticoid) Secondary efficacy outcome 1) peak FEV1 & FVC at each treatment visit 2) trough FEV1 & FVC at each treatment visit 3) time to the 1st worsening of Asthma ( Sx ↑ or decline of >30% PEF)

56 days

Tiotropium : In patients with poorly controlled asthma despite treatment with inhaled glucocorticoids and LABAs, adding tiotropium significantly reduced the risk of episodes of the worsening of asthma and asthma exacerbations and provided sustained bronchodilation.